信迪利单抗联合西达苯胺和贝伐珠单抗治疗MSS/pMMR结肠直肠癌患者的临床研究

引自:WANG F,et al.Combined anti-PD-1,HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer:A randomized phase 2 trial[J].Nat Med,2024,30(4):1035—1043.中山大学肿瘤防治中心WANG团队在开展了一项随机、2期CAPability-01研究,旨在评估程序性细胞死亡蛋白-1(programmed celldeath protein-1,PD-1)单克隆抗体信迪利单抗与组蛋白脱乙酰酶抑制药(histone deacetylase inhibitor,HDACi)西达苯胺联合或不联合抗血管内皮生长因子(vascular endothelial growth factor,VEGF)单克隆抗体贝伐珠单抗治疗不可切除的、难治性局部晚期或转移性微卫星稳定/错配修复系统完善型(metastatic microsatellite stable/proficient mismatch repair,MSS/pMMR)结直肠癌患者的临床疗效。